

Combination therapy for BPH: Prostating the not-so obvious truth!

Marina Barsoum

References

1. DynaMed. Benign Prostatic Hyperplasia (BPH). EBSCO Information Services. Accessed October 12, 2022. <https://www.dynamed.com/condition/benign-prostatic-hyperplasia-bph>
2. Elterman D, Aubé-Peterkin M, Evans H, Elmansy H, Meskawi M, Zorn KC et al. UPDATE – Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia. *Can Urol Assoc J* 2022;16(8):245-56. <http://dx.doi.org/10.5489/cuaj.7906>
3. Norman RW. Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. In: Therapeutic Choices [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2019 [updated May 2021; cited 2022 Oct 12]. Available from: <http://www.e-therapeutics.ca>
4. Füllhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Kaplan SA et al. Systematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms. *Eur Urol* 2013 Aug; 64(2):228-43.
5. Pang R, Zhou X-Y, Wang X, Wang B, Yin X-L, Bo H et al. Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. *Cochrane Database of Systematic Reviews* [Internet]. 2021 [cited 2022 Oct 12]; Issue 2. Art. No.: CD012336. Available from: DOI: 10.1002/14651858.CD012336.pub2.
6. Pattanaik S, Mavuduru RS, Panda A, Mathew JL, Agarwal MM, Hwang EC, et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. *Cochrane Database of Systematic Reviews* [Internet]. 2018 [cited 2022 Oct 12]; Issue 11. Art. No.: CD010060. Available from: DOI: 10.1002/14651858.CD010060.pub2.